Kardigan has made a strong public market entrance, with shares jumping more than 37% on its first day of trading following a $400 million initial public offering that underscores continued investor appetite for biotech listings. The cardiovascular-focused company upsized its IPO ahead of pricing, ultimately selling 25 million shares at $16 each, the top end of its revised range. The offering had initially targeted 23.3 million shares priced between $14 and $16. The debut places Kardigan among the largest biotech IPOs of 2026 so far, tied for third alongside Generate:Biomedicines. It follows closely behind Parabilis Medicines, which raised $670 million, and Kailera Therapeutics, which raised $625 million in earlier listings this year. Strong First-Day Performance Signals Continued Biotech Risk Appetite The sharp first-day gain reflects sustained investor demand for differentiated biotech assets despite a volatile funding environment. Public market enthusiasm has been particularly concentrated in companies with clearly defined therapeutic areas and late-stage or de-risked clinical programmes, with cardiovascular disease emerging as a notable area of interest alongside oncology and obesity. Kardigan’s listing adds further momentum to what has already been a record-setting year for biotech IPO activity. Pipeline Built Around Cardiovascular Disease Mechanisms Proceeds from the IPO will be used to advance Kardigan’s pipeline of therapies targeting the underlying mechanisms of cardiovascular disease. The company’s lead asset, danicamtiv, was in-licensed from Bristol Myers Squibb and is currently being evaluated in the Phase IIb/III KINSHIP-DCM study in patients with genetic dilated cardiomyopathy associated with MYH7 and TTN mutations. Danicamtiv sits at the centre of Kardigan’s strategy to address inherited and mechanistic drivers of cardiac dysfunction rather than symptom management alone. The company is also developing ataciguat, an oral soluble guanylate cyclase activator, currently in a Phase IIb study for calcific aortic valve stenosis under the KATALYST-AV trial. A third programme, tonlamarsen, is a liver-directed antisense oligonucleotide in Phase II development for severe hypertension following hospitalisation in the KARDINAL-ASH study. Each asset targets distinct but interconnected cardiovascular pathways, reflecting a broader industry shift toward mechanism-based approaches in cardiometabolic disease. IPO Market Continues to Favour Defined Clinical Narratives Kardigan’s successful debut adds to a growing pattern in biotech public offerings, where investor attention has increasingly gravitated toward companies with clear mechanistic hypotheses and focused disease areas. Cardiovascular disease, long considered a challenging but high-value therapeutic area, is seeing renewed interest as genetic insights and precision medicine approaches reshape development strategies. The strong IPO performance suggests that, despite broader market uncertainty, capital remains available for companies with credible clinical differentiation and defined late-stage assets. A Strong Start, but Clinical Execution Now in Focus While the IPO marks a successful entry into public markets, Kardigan now faces the next phase of scrutiny as it advances its clinical programmes toward key data readouts. The company’s ability to translate its mechanistic pipeline into clinical and regulatory success will ultimately determine whether early investor enthusiasm is sustained beyond the initial trading momentum. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The spin-out creates a dedicated US oncology company to raise capital and advance Lupin’s PRMT5 and SOS1 programmes through global clinical development. Lupin has granted Kaveri Therapeutics exclusive, perpetual licences to two clinical-stage oncology programmes—LNP7457 and LNP8701—in exchange for an 82.2% equity stake, with the assets valued at $1.6 million. The arrangement is intended to accelerate their development through an independently managed oncology company that will seek external funding for global clinical trials. Field Content Alert Type Deal Companies Lupin Inc., the wholly owned US subsidiary of Lupin Limited, and Kaveri Therapeutics Deal Type Strategic spin-out and exclusive perpetual licensing agreement involving an 82.2% equity stake Asset or Company LNP7457, a PRMT5-targeting programme, and LNP8701, a SOS1-targeting programme Therapy Area(s) Oncology Technology or Modality Targeted small-molecule oncology therapies Deal Value The two licensed programmes were valued at $1.6 million. Lupin received 332,000 common shares representing an 82.2% stake in Kaveri and will also provide seed funding, the amount of which was not disclosed. Development Stage Clinical-stage programmes in early clinical development Geography US-based transaction with planned global clinical development What Happened Lupin granted Kaveri exclusive, perpetual licences to LNP7457 and LNP8701 in exchange for an 82.2% equity stake. The transaction was completed on 20 July 2026, and Kaveri will assume responsibility for advancing the programmes through global clinical trials. Background Kaveri was incorporated in Delaware in May 2026 as a clinical-stage oncology company focused on solid tumours, including lung, pancreatic, ovarian and CNS-related cancers. Lupin reported that LNP7457 and LNP8701 presented positive clinical data at the 2025 and 2026 ASCO meetings, respectively. Strategic Rationale The structure places the two programmes within a dedicated, independently managed oncology company that can raise external capital and focus on global clinical development, while Lupin retains a majority equity interest in their future progress. Why It Matters The deal gives the programmes a specialised development vehicle and access to additional financing without Lupin relinquishing its majority economic interest. It also expands Kaveri’s pipeline across two targeted mechanisms relevant to difficult-to-treat solid tumours. Potential Impact Successful fundraising could support broader global trials and biomarker-driven development of the PRMT5 and SOS1 programmes, although their eventual clinical and commercial value will depend on future trial results. Key Takeaway Lupin is using a majority-owned spin-out to pursue external funding and focused clinical development for two targeted oncology assets. What to Watch Kaveri’s planned capital raise, the design and progression of global clinical trials, future data from both programmes and any additional financing or partnership arrangements. Source Link Lupin regulatory filing and accompanying company press release Deal Date 21 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The two-year tariff-free window could prompt overseas manufacturers and US importers to reassess production, investment and sourcing before higher duties take effect. President Donald Trump has announced that generic drugs imported into the US will remain subject to a zero tariff for two years from 1 August 2026, followed by a 100% tariff for one year and a 200% tariff thereafter. If formalised, the timetable could materially change the economics of supplying the US generics market and increase pressure on manufacturers to establish domestic production. Field Content Alert Type Industry Update Topic Trade policy and pharmaceutical manufacturing Organisation(s) US administration; President Donald Trump Affected Stakeholders Overseas generic-drug manufacturers, US pharmaceutical importers and companies reliant on imported generic products or ingredients Geography US What Happened Trump announced that imported generic drugs would retain a zero tariff for two years from 1 August 2026. The announced rate would then rise to 100% for one year and 200% thereafter, with the stated aim of encouraging generic-drug manufacturers to build production capacity in the US. The announcement did not itself provide the formal tariff classifications, exemptions or implementation mechanism. Why It Matters The proposed rates could substantially alter manufacturing and sourcing decisions for companies supplying generic medicines to the US. The two-year transition gives affected businesses time to evaluate domestic investment, but the commercial consequences will depend on the final scope and rules. Supporting Context An April 2026 presidential proclamation imposed tariffs on certain patented pharmaceutical products but stated that generic pharmaceuticals, associated ingredients and biosimilars would not be subject to Section 232 tariffs at that time. It also required the Department of Commerce to report within one year on circumstances that might support further action on generic imports. Who Is Most Affected Foreign manufacturers supplying generic medicines to the US face the clearest potential exposure. US importers may need to review suppliers and costs, while domestic manufacturers could gain a stronger incentive to expand capacity. Industry Impact If implemented as announced, the policy could accelerate US manufacturing investment and encourage supply-chain restructuring. Its effect on medicine costs, competition and availability would depend on whether manufacturers can establish sufficient domestic capacity and on any exemptions included in the formal rules. Key Takeaway Generic-drug manufacturers have been given an announced two-year planning window, but formal implementation details will determine which products and companies are ultimately affected. What to Watch A presidential proclamation, Federal Register notice or Department of Commerce guidance confirming the legal basis, covered tariff codes, treatment of active pharmaceutical ingredients and biosimilars, exemptions and criteria for qualifying US investment. Primary Source President Donald Trump’s Truth Social announcement Relevant Date 21 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com